Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px
Organisation › Details

Neovacs S.A. (Euronext Growth Paris: ALNEV)

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNa Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. *


Period Start 2010-05-21 existent
  Group Neovacs (Group)
Products Industry therapeutic vaccine
  Industry 2 TNF-Kinoid
Persons Person Sieler, Miguel (Neovacs 201310 CEO before Bayer France CEO at Bayer since 1975)
  Person 2 Fanneau de la Horie, Guy-Charles (Pherecydes Pharma 201602– CEO before PathoQuest + Neovacs + Biogen)
Region Region Paris
  Country France
  Street 3–5 Impasse Reille
  City 75014 Paris
  Tel +33-1-5310-9300
    Address record changed: 2024-01-05
Basic data Employees B: 11 to 50 (2014-11-01)
  Currency EUR
  Annual sales 394,000 (revenues (2016) 2016-12-31)
  Profit -13,932,000 (2016-12-31)
  Cash 3,900,000 (2016-12-31)
    * Document for »About Section«: Neovacs S.A.. (2/22/18). "Press Release: Neovacs Strengthens Its Intellectual Property in the USA". Paris & Boston, MA.
Record changed: 2024-02-12


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Neovacs (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px

» top